Oragenics, makers of ProBiora probiotic treatment for oral diseases, has received a National Science Foundation grant of $500,000 to support its research into a new antibiotic with potential against bacteria resistant to other antibiotics.
The money supplements a previous grant to support the company's lantibiotic synthesis platform. The antibiotics made with the platform have proved effective preclinically against Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and Clostridium, according to Oragenics.
Oragenics sells SMaRT replacement therapy, "a one-time treatment that provides a potential lifetime prevention of dental caries (tooth decay);" the antibiotic MU 1140; and ProBiora3, "a technology that whitens teeth, freshens breath, and supports gum and tooth health." ProBiora3 is incorporated into the company's three over-the-counter products: EvoraPlus, EvoraKids, and Teddy's Pride.
Copyright © 2010 DrBicuspid.com
